OncoSTING is developing novel bladder cancer therapies by harnessing the potency of standard BCG immunotherapy
OncoSTING has raised $256K in total funding. The most recent round was Grant. The last funding was announced in June 2022.
OncoSTING's investors include National Science Foundation, Maryland Innovation Initiative (MII).
OncoSTING is headquartered in Baltimore, United States.
OncoSTING is developing novel bladder cancer therapies by harnessing the potency of standard BCG immunotherapy
OncoSTING is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OncoSTING — Funding & Investors." VCBacked, June 1, 2022, https://www.vcbacked.co/company/oncosting. Accessed August 15, 2026.
VCBacked. (2022). OncoSTING — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/oncosting
{{cite web |title=OncoSTING — Funding & Investors |url=https://www.vcbacked.co/company/oncosting |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated